Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients

Trial Profile

Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Abemaciclib (Primary) ; Caffeine; Dextromethorphan; Midazolam; Warfarin
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 31 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 May 2018.
    • 18 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017.
    • 18 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top